ArticleThe journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG2025
The Current State of Unapproved Cannabidiol Product Use in Children.
Article in The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cannabidiol (CBD) is a naturally occurring cannabinoid isolated from Cannabis sativa. CBD has therapeutic benefit for the treatment of seizures associated with various epilepsy syndromes in children; however, data are lacking related to the use of CBD for other indications in pediatric patients. Despite this lack of clinical data, the use of CBD products as a complementary treatment for various conditions in children continues to increase. Thus, it is imperative that those involved in the care of children and adolescents are well informed with current information related to CBD use in pediatrics. This review will address the pharmacology of CBD, legal and regulatory factors, usage patterns, current efficacy data, and safety concerns related to the use of CBD in children and adolescents. Recommendations for clinicians, public health officials, and researchers are also provided to effectively manage the use of unapproved CBD products in the pediatric population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.